These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9857253)

  • 21. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients.
    Beckers RC; Brand A; Vermeer BJ; Boom BW
    Br J Dermatol; 1995 Aug; 133(2):289-93. PubMed ID: 7547400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunoadsorption in the treatment of pemphigus.
    Mlynek A; Meurer M
    Atheroscler Suppl; 2009 Dec; 10(5):107-9. PubMed ID: 20129386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Steroid sparing effect of intravenous immunoglobulin therapy in patients with pemphigus foliaceus.
    Sami N; Qureshi A; Ahmed AR
    Eur J Dermatol; 2002; 12(2):174-8. PubMed ID: 11872417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of pemphigus with intravenous immunoglobulin.
    Bystryn JC; Jiao D; Natow S
    J Am Acad Dermatol; 2002 Sep; 47(3):358-63. PubMed ID: 12196744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris.
    Sami N; Qureshi A; Ruocco E; Ahmed AR
    Arch Dermatol; 2002 Sep; 138(9):1158-62. PubMed ID: 12224976
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comment on the contribution by Alexander H. Enk and Jürgen Knop. "Adjuvant therapy of pemphigus vulgaris and pemphigus foliaceus with intravenous immunoglobulins"].
    Luther H; Kastner U; Altmeyer P
    Hautarzt; 1999 May; 50(5):372-4. PubMed ID: 10412638
    [No Abstract]   [Full Text] [Related]  

  • 28. An 'n-of-1' placebo-controlled crossover trial of intravenous immunoglobulin as adjuvant therapy in refractory pemphigus vulgaris.
    Arnold DF; Burton J; Shine B; Wojnarowska F; Misbah SA
    Br J Dermatol; 2009 May; 160(5):1098-102. PubMed ID: 19222460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of pemphigus vulgaris with high-dose intravenous immunoglobulins in a patient with steroid-induced osteonecrosis of the femoral head].
    Giesecke E; Enk A; Kerstin S
    J Dtsch Dermatol Ges; 2004 May; 2(5):354-6. PubMed ID: 16281524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immunoglobulin therapy for patients with pemphigus foliaceus unresponsive to conventional therapy.
    Ahmed AR; Sami N
    J Am Acad Dermatol; 2002 Jan; 46(1):42-9. PubMed ID: 11756944
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 6-year treatment experience for pemphigus: retrospective study of 69 Chinese patients.
    Bai YX; Zhang LM; Xiao T; Chen HD
    Dermatol Ther; 2016; 29(2):84-7. PubMed ID: 27060935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris.
    Olszewska M; Kolacinska-Strasz Z; Sulej J; Labecka H; Cwikla J; Natorska U; Blaszczyk M
    Am J Clin Dermatol; 2007; 8(2):85-92. PubMed ID: 17428113
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mycophenolate is effective in the treatment of pemphigus vulgaris.
    Enk AH; Knop J
    Arch Dermatol; 1999 Jan; 135(1):54-6. PubMed ID: 9923781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Catabolism of pemphigus foliaceus autoantibodies by high-dose IVIg therapy.
    Aoyama Y; Moriya C; Kamiya K; Nagai M; Rubenstein D; Iwatsuki K; Kitajima Y
    Eur J Dermatol; 2011; 21(1):58-61. PubMed ID: 21233063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical transition between pemphigus foliaceus and pemphigus vulgaris correlates well with the changes in autoantibody profile assessed by an enzyme-linked immunosorbent assay.
    Komai A; Amagai M; Ishii K; Nishikawa T; Chorzelski T; Matsuo I; Hashimoto T
    Br J Dermatol; 2001 Jun; 144(6):1177-82. PubMed ID: 11422038
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant high-dose intravenous immunoglobulin therapy can be easily and safely introduced as an alternative treatment in patients with severe pemphigus vulgaris: a retrospective preliminary study.
    Mignogna MD; Leuci S; Fedele S; Ruoppo E; Adamo D; Russo G; Pagliuca R
    Am J Clin Dermatol; 2008; 9(5):323-31. PubMed ID: 18717608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current therapy of the pemphigus group.
    Kasperkiewicz M; Schmidt E; Zillikens D
    Clin Dermatol; 2012; 30(1):84-94. PubMed ID: 22137231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First line treatment of pemphigus vulgaris with a novel protocol in patients with contraindications to systemic corticosteroids and immunosuppressive agents: Preliminary retrospective study with a seven year follow-up.
    Ahmed AR; Nguyen T; Kaveri S; Spigelman ZS
    Int Immunopharmacol; 2016 May; 34():25-31. PubMed ID: 26919279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: A systematic review.
    Tavakolpour S; Mahmoudi H; Balighi K; Abedini R; Daneshpazhooh M
    Int Immunopharmacol; 2018 Jan; 54():131-138. PubMed ID: 29132070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.